Clinical

CLINUVEL
Posted by CLINUVEL
July 28, 2022

PRÉNUMBRA® for stroke

Melbourne, Australia, 28 July 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
May 10, 2022

CLINUVEL progresses vitiligo treatment program

A new potential therapy for the pigment loss disorder vitiligo will undergo...

Read More
CLINUVEL
Posted by CLINUVEL
May 4, 2022

Positive final results in stroke

CLINUVEL today released positive final results of the open label pilot study...

Read More
Lachlan Hay
Posted by Lachlan Hay
April 1, 2022

CLINUVEL Extends Employment Agreement With CEO

CLINUVEL today announced that it has extended the Employment Agreement with the...

Read More
CLINUVEL
Posted by CLINUVEL
April 1, 2022

DNA Repair Communiqué II

In this DNA Repair Communiqué II we delve deeper into the topic...

Read More
CLINUVEL
Posted by CLINUVEL
March 30, 2022

First XP-V Patient Treated in CLINUVEL DNA Repair Study

CLINUVEL today announced that the first disease-free subjects have received afamelanotide as...

Read More
CLINUVEL
Posted by CLINUVEL
March 15, 2022

Afamelanotide in stroke (AIS) – positive preliminary results

CLINUVEL today released positive preliminary results from its pilot study (CUV801) in...

Read More
CLINUVEL
Posted by CLINUVEL
February 15, 2022

DNA Repair Communiqué I

This first Communiqué in a series on DNA forms an introductory foundation,...

Read More
CLINUVEL
Posted by CLINUVEL
February 14, 2022

CLINUVEL Expands DNA Repair Program with 2nd DNA Repair Study

CLINUVEL today announced that the first disease-free subjects have received afamelanotide as...

Read More
CLINUVEL
Posted by CLINUVEL
January 24, 2022

SCENESSE® continued in Germany

CLINUVEL today announced that it has entered a second agreement with the...

Read More
CLINUVEL
Posted by CLINUVEL
January 17, 2022

CLINUVEL completes enrolment in world-first stroke study

CLINUVEL today announced that it has completed enrolment in its world-first study...

Read More
CLINUVEL
Posted by CLINUVEL
December 20, 2021

Vitiligo Communiqué IV

CLINUVEL’s fourth Vitiligo Communiqué discusses the long-term consequences, both physical and psychological,...

Read More
CLINUVEL
Posted by CLINUVEL
October 22, 2021

First Patient Treated in CLINUVEL DNA Repair Study

Melbourne, Australia, 22 October 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
October 5, 2021

CLINUVEL Progresses DNA Repair Program

Melbourne, Australia, 05 October 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
August 10, 2021

Afamelanotide well tolerated by first stroke patients

CLINUVEL’s drug afamelanotide was well tolerated by the first three arterial ischaemic...

Read More